Azemar P - Search Results

1

Influence of recent climatic events on the surface water storage of the Tonle Sap Lake.

Frappart F, Biancamaria S, Normandin C, Blarel F, Bourrel L, Aumont M, Azemar P, Vu PL, Le Toan T, Lubac B, Darrozes J. Frappart F, et al. Among authors: azemar p. Sci Total Environ. 2018 Sep 15;636:1520-1533. doi: 10.1016/j.scitotenv.2018.04.326. Epub 2018 May 7. Sci Total Environ. 2018. PMID: 29913613

2

Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study.

Mahé I, Bergmann JF, d'Azémar P, Vaissie JJ, Caulin C. Mahé I, et al. Among authors: d azemar p. Eur J Clin Pharmacol. 2005 Jul;61(5-6):347-51. doi: 10.1007/s00228-005-0944-3. Epub 2005 Jun 25. Eur J Clin Pharmacol. 2005. PMID: 15981008 Clinical Trial.

3

Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis.

Meignan M, Rosso J, Gauthier H, Brunengo F, Claudel S, Sagnard L, d'Azemar P, Simonneau G, Charbonnier B. Meignan M, et al. Among authors: d azemar p. Arch Intern Med. 2000 Jan 24;160(2):159-64. doi: 10.1001/archinte.160.2.159. Arch Intern Med. 2000. PMID: 10647753

4

Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).

Mismetti P, Laporte-Simitsidis S, Navarro C, Sié P, d'Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B. Mismetti P, et al. Among authors: d azemar p. Thromb Haemost. 1998 Jun;79(6):1162-5. Thromb Haemost. 1998. PMID: 9657442 Clinical Trial.

5

Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.

Charbonnier BA, Fiessinger JN, Banga JD, Wenzel E, d'Azemar P, Sagnard L. Charbonnier BA, et al. Among authors: d azemar p. Thromb Haemost. 1998 May;79(5):897-901. Thromb Haemost. 1998. PMID: 9609216 Clinical Trial.

6

Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.

Boneu B, Navarro C, Cambus JP, Caplain H, d'Azemar P, Necciari J, Duret JP, Gaud C, Sié P. Boneu B, et al. Among authors: d azemar p. Thromb Haemost. 1998 Feb;79(2):338-41. Thromb Haemost. 1998. PMID: 9493587 Clinical Trial.

7

Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale.

Lablanche JM, McFadden EP, Meneveau N, Lusson JR, Bertrand B, Metzger JP, Legrand V, Grollier G, Macaya C, de Bruyne B, Vahanian A, Grentzinger A, Masquet C, Wolf JE, Tobelem G, Fontecave S, Vacheron A, d'Azemar P, Bertrand ME. Lablanche JM, et al. Among authors: d azemar p. Circulation. 1997 Nov 18;96(10):3396-402. doi: 10.1161/01.cir.96.10.3396. Circulation. 1997. PMID: 9396433 Clinical Trial.

8

Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.

Nurmohamed MT, van Riel AM, Henkens CM, Koopman MM, Que GT, d'Azemar P, Büller HR, ten Cate JW, Hoek JA, van der Meer J, van der Heul C, Turpie AG, Haley S, Sicurella A, Gent M. Nurmohamed MT, et al. Among authors: d azemar p. Thromb Haemost. 1996 Feb;75(2):233-8. Thromb Haemost. 1996. PMID: 8815566 Clinical Trial.

9

Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study.

Théry C, Simonneau G, Meyer G, Hélénon O, Bridey F, Armagnac C, d'Azemar P, Coquart JP. Théry C, et al. Among authors: d azemar p. Circulation. 1992 Apr;85(4):1380-9. doi: 10.1161/01.cir.85.4.1380. Circulation. 1992. PMID: 1313340 Clinical Trial.

10

Influence of thromboembolism prophylaxis by low molecular weight heparin CY 216 (Fraxiparine) on several parameters of haemostasis in patients under dialysis and receiving either unfractionated heparin or CY 216.

Diéval J, Morinière P, Gross S, d'Azemar P, Fournier A, Delobel J. Diéval J, et al. Among authors: d azemar p. Thromb Res. 1990 Jun 15;58(6):555-60. doi: 10.1016/0049-3848(90)90301-r. Thromb Res. 1990. PMID: 2166971 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters